a biotechnology company focused on gastrointestinal diseases that was acquired by Merck for $10.8 billion in 2023. Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently ...

a biotechnology company focused on gastrointestinal diseases that was acquired by Merck for $10.8 billion in 2023. Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently ...

BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

For AbbVie, the good news this week is that the ... The bad news is that the effort might not get any easier. The company has had high hopes for the schizophrenia treatment, called emraclidine ...